Publicaciones (25) Publicaciones de Miguel Burgos Lozano

2024

  1. The glucose transporter GLUT12, a new actor in obesity and cancer

    Journal of Physiology and Biochemistry

2023

  1. Maresin 1 Exerts a Tissue-Specific Regulation of Adipo-Hepato-Myokines in Diet-Induced Obese Mice and Modulates Adipokine Expression in Cultured Human Adipocytes in Basal and Inflammatory Conditions

    Biomolecules, Vol. 13, Núm. 6

2022

  1. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  2. Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. MZ1 co-operates with trastuzumab in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  2. The p.E152K-STIM1 mutation deregulates Ca2+ signaling contributing to chronic pancreatitis

    Journal of Cell Science, Vol. 134, Núm. 3

2020

  1. Checkpoint kinase 1 pharmacological inhibition synergizes with dna-damaging agents and overcomes platinum resistance in basal-like breast cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-14

  2. Crocetin isolated from the natural food colorant saffron reduces intracellular fat in 3T3-L1 adipocytes

    Foods, Vol. 9, Núm. 11

  3. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer

    Cellular Oncology, Vol. 43, Núm. 3, pp. 431-444

  4. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer

    Cancer Letters, Vol. 491, pp. 50-59

  5. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127

2019

  1. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1

  2. STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia

    Journal for ImmunoTherapy of Cancer, Vol. 7, Núm. 1

  3. Trastuzumab-targeted biodegradable nanoparticles for enhanced delivery of dasatinib in HER2+ metastasic breast cancer

    Nanomaterials, Vol. 9, Núm. 12

  4. Visualization of mitochondrial Ca2+ signals in skeletal muscle of zebrafish embryos with bioluminescent indicators

    International Journal of Molecular Sciences, Vol. 20, Núm. 21

2018

  1. CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes

    Cellular and Molecular Immunology, Vol. 15, Núm. 2, pp. 158-170

2017

  1. Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer

    Molecular Cancer Therapeutics, Vol. 16, Núm. 11, pp. 2552-2562

  2. Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors

    Oncotarget, Vol. 8, Núm. 12, pp. 19478-19490

2011

  1. A proteomic analysis of PKCε targets in astrocytes: Implications for astrogliosis

    Amino Acids, Vol. 40, Núm. 2, pp. 641-651

2010

  1. Caspase-11 mediates ischemia-induced astrocyte death: Involvement of endoplasmic reticulum stress and C/EBP homologous protein

    Journal of Neuroscience Research, Vol. 88, Núm. 5, pp. 1094-1105